RAD · Rite Aid Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Revenue | $24.09B | $24.57B | $24.04B | $21.53B | $22.93B | $21.53B |
| Cost of Revenue | $19.29B | $19.46B | $19.34B | $17.20B | $16.96B | $16.75B |
| Gross Profit | $4.80B | $5.11B | $4.70B | $4.73B | $4.68B | $4.78B |
| R&D | - | - | - | - | - | - |
| SG&A | $4.90B | $5.03B | $4.66B | $4.59B | $4.59B | $4.65B |
| Total Operating Expenses | $24.85B | $25.11B | $24.16B | $22.01B | $22.23B | $21.57B |
| D&A | $276.58M | $295.69M | $327.12M | $328.28M | $357.88M | $386.06M |
| Operating Income | ($756.40M) | ($542.26M) | ($120.23M) | ($81.61M) | ($589.48M) | ($43.55M) |
| Interest Expense | $224.40M | $191.60M | $201.39M | $229.66M | $227.73M | $202.77M |
| Income Tax | ($6.47M) | ($3.78M) | ($20.16M) | $387.61M | $77.48M | $305.99M |
| Net Income | ($749.94M) | ($538.48M) | ($90.91M) | ($452.17M) | ($422.21M) | $943.47M |
| EPS - Basic | ($13.71) | ($9.96) | ($1.69) | ($8.50) | ($7.99) | $0.90 |
| EPS - Diluted | ($13.71) | ($9.96) | ($1.69) | ($8.50) | ($7.99) | $0.90 |
Balance Sheet
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $157.15M | $39.72M | $160.90M | $218.18M | $144.35M | $447.33M |
| Accounts Receivable | $1.15B | $1.34B | $1.46B | $1.29B | $1.79B | $1.87B |
| Inventory | $1.90B | $1.96B | $1.86B | $1.92B | $1.87B | $1.80B |
| Accounts Payable | $1.49B | $1.57B | $1.44B | $1.48B | $1.62B | $1.65B |
| Current Assets | $3.30B | $3.45B | $3.60B | $3.70B | $4.10B | $4.74B |
| Total Assets | $7.53B | $8.53B | $9.34B | $9.45B | $7.59B | $8.99B |
| Current Liabilities | $2.73B | $2.93B | $2.60B | $2.77B | $2.44B | $3.46B |
| Long-term Debt | $2.93B | $2.73B | $3.06B | $3.08B | $3.45B | $3.34B |
| Total Liabilities | $8.17B | $8.43B | $8.72B | $8.78B | $6.40B | $7.39B |
| Stockholders' Equity | ($641.78M) | $99.03M | $615.15M | $674.53M | $1.19B | $1.60B |
| Retained Earnings | ($6.60B) | ($5.85B) | ($5.31B) | ($5.22B) | ($4.71B) | ($4.28B) |
Cash Flow
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($52.44M) | $379.27M | $105.18M | $510.86M | ($165.71M) | $511.47M |
| Investing Cash Flow | ($104.76M) | ($134.07M) | ($109.33M) | ($149.85M) | ($198.55M) | ($182.94M) |
| Financing Cash Flow | $274.63M | ($366.38M) | ($65.24M) | ($326.65M) | $803.29M | ($237.58M) |
| CapEx | $215.28M | $194.09M | $195.14M | $171.71M | $196.78M | $185.88M |
| Free Cash Flow | ($267.72M) | $185.18M | ($89.96M) | $339.15M | ($362.49M) | $325.59M |
Ratios
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 19.9% | 20.8% | 19.6% | 22.0% | 20.4% | 22.2% |
| Operating margin | -3.1% | -2.2% | -0.5% | -0.4% | -2.6% | -0.2% |
| EBITDA margin | -2.0% | -1.0% | 0.9% | 1.1% | -1.0% | 1.6% |
| Net margin | -3.1% | -2.2% | -0.4% | -2.1% | -1.8% | 4.4% |
| Free cash flow margin | -1.1% | 0.8% | -0.4% | 1.6% | -1.6% | 1.5% |
| FCF / Net income | 0.36 | -0.34 | 0.99 | -0.75 | 0.86 | 0.35 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 20.3% | 20.5% | 19.4% | 21.3% | 20.0% | 21.6% |
| Effective tax rate | - | - | - | - | - | 24.5% |
| Return on assets | -10.0% | -6.3% | -1.0% | -4.8% | -5.6% | 10.5% |
| Return on equity | 116.9% | -543.7% | -14.8% | -67.0% | -35.6% | 58.9% |
| Return on invested capital | -26.2% | -15.1% | -2.6% | -1.7% | -10.0% | -0.7% |
| Liquidity | ||||||
| Current ratio | 1.21 | 1.18 | 1.38 | 1.34 | 1.68 | 1.37 |
| Quick ratio | 0.51 | 0.51 | 0.66 | 0.64 | 0.91 | 0.85 |
| Cash ratio | 0.06 | 0.01 | 0.06 | 0.08 | 0.06 | 0.13 |
| Leverage | ||||||
| Debt / Equity | -4.56 | 27.60 | 4.98 | 4.56 | 2.91 | 2.09 |
| Debt / Assets | 0.39 | 0.32 | 0.33 | 0.33 | 0.46 | 0.37 |
| Debt / EBITDA | - | - | 14.80 | 12.48 | - | 9.75 |
| Interest coverage | -3.4x | -2.8x | -0.6x | -0.4x | -2.6x | -0.2x |
| Equity multiplier | -11.73 | 86.12 | 15.18 | 14.01 | 6.40 | 5.61 |
| Liabilities / Assets | 1.09 | 0.99 | 0.93 | 0.93 | 0.84 | 0.82 |
| Efficiency | ||||||
| Asset turnover | 3.20 | 2.88 | 2.58 | 2.28 | 3.02 | 2.39 |
| Inventory turnover | 10.15 | 9.93 | 10.37 | 8.95 | 9.06 | 9.31 |
| Days sales outstanding | 17d | 20d | 22d | 22d | 28d | 32d |
| Days inventory outstanding | 36d | 37d | 35d | 41d | 40d | 39d |
| Days payable outstanding | 28d | 29d | 27d | 31d | 35d | 36d |
| Cash conversion cycle | 25d | 27d | 30d | 31d | 34d | 35d |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -1.9% | 2.2% | 11.7% | -6.1% | 6.5% | -34.5% |
| Revenue CAGR (3y) | 3.8% | 2.3% | 3.8% | -13.1% | -9.3% | -6.7% |
| Revenue CAGR (5y) | 2.3% | -5.6% | -4.8% | -4.1% | - | -3.3% |
| Gross profit growth (YoY) | -5.9% | 8.5% | -0.5% | 1.1% | -2.2% | -38.5% |
| Operating income growth (YoY) | -39.5% | -351.0% | -47.3% | 86.2% | -1253.7% | - |
| Net income growth (YoY) | -39.3% | -492.3% | 79.9% | -7.1% | - | 23178.3% |
| EPS growth (YoY) | -37.7% | -489.3% | 80.1% | -6.4% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | -24.4% |
| EPS CAGR (5y) | - | - | - | - | - | 31.4% |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | 8.8% | - | -2.4% |
| Book value growth (YoY) | - | -83.9% | -8.8% | -43.2% | -25.9% | 160.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-03-04.
Business segments
$29.39B totalRetail Pharmacy$17.79B · 60.5%
Pharmacy Services$6.52B · 22.2%
Front End Sales$5.08B · 17.3%
Product / service
$17.66B totalPharmacy Sales$12.58B · 71.2%
Front End Sales$5.08B · 28.8%
Stability scores
Altman Z′
FY 2023 · bankruptcy risk
2.16
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2023 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Retail-Drug Stores and Proprietary Stores
Comparing RITE AID CORP against the 5 most active filers in the same SIC group.